Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine

Authors:	Email author" target="_blank">Abouch?Valenty?Krymchantowski Email author Marcelo?Eduardo?Bigal

Institution:	1.Department of Neurology,Universidade Federal Fluminense,Niterói,Brazil;2.Headache Outpatient Unit,Instituto de Neurologia Deolindo Couto,Rio de Janeiro,Brazil;3.Headache Center of Rio,Rio de Janeiro,Brazil;4.Department of Neurology,The Albert Einstein College of Medicine,Bronx,USA;5.Research Department,The New England Center for Headache,Stamford,USA

Abstract:	Background Rizatriptan is an effective and fast acting drug for the acute treatment of migraine. Some nonsteroidal anti-inflammatory drugs (NSAID) have also demonstrated efficacy in treating migraine attacks. There is evidence that the combination of a triptan and a NSAID decreases migraine recurrence in clinical practice. The primary aim of this randomized open label study was to assess the recurrence rates in migraine sufferers acutely treated with rizatriptan (RI) alone vs. rizatriptan plus a COX-2 enzyme inhibitor (rofecoxib, RO) vs. rizatriptan plus a traditional NSAID (tolfenamic acid, TO). We were also interested in comparing the efficacy rates within these three groups.

Keywords:
本文献已被 SpringerLink 等数据库收录！